Recent years have seen the development of a number of new small molecule therapies for the treatment of myeloma and as a result of their introduction there have been significant improvements in patient survival. However, patients continue to relapse, and the current challenge is to develop therapies able to effectively treat these refractory cases. An emerging feature of the use of single, highly specific molecules is that they can be clinically ineffective because of the redundancy in the pathway targeted and compensatory changes induced by drug exposure. Consequently therapeutic efficacy is reliant on the development of effective combinations targeting synergistic pathways.
A simplified view of the function and biology of plasma cells is that they exist to produce immunoglobulin and this can provide a differential marker, which can be targeted. The requirement for immunoglobulin production means that the myeloma plasma cell is reliant upon the unfolded protein response (UPR) and molecular chaperones for survival. 1 Heat shock protein (Hsp) 90 is a molecular chaperone that has an important role in the pathophysiology of myeloma and represents a relevant therapeutic target. 2, 3 It fulfils two essential roles in plasma cells: firstly it is a major pro-survival chaperone, which associates with and stabilizes an extensive range of signal transducers important to plasma cell survival and proliferation (insulin-like growth factor-1, vascular endothelial growth factor, RAF and p42/44 mitogenactivated protein kinase), cell cycle regulation (AKT and nuclear factor-kB), migration (phosphoinositide 3-kinase) and antiapoptotic (nuclear factor-kB) pathways. Secondly, it has a central role in the UPR, which is responsible for ensuring the correct folding of nascent immunoglobulin, as well as providing survival signals for clonal expansion. Although targeting these pathways using inhibitors of Hsp90 has proved successful in myeloma preclinical models, preliminary results in patients suggest that combinations of agents will be required for clinical use.
To provide a rationale for the development of effective mechanism-based clinical combinations, we have tested the hypothesis that the induction of the Hsp70 family member, Hsp72, after treatment with an Hsp90 inhibitor, protects myeloma cells from apoptosis by enabling cells to increase their ability to fold damaged proteins. Hence inhibition of the function of Hsp72 may enhance the apoptosis induced by Hsp90 inhibition. We have therefore investigated the role of Hsp72 in myeloma using two chemical compounds, which have been shown to inhibit the protective effects of Hsp70, triptolide and KNK437. To confirm the impact of Hsp72 inhibition, we have verified these findings using small hairpin RNA (shRNA) specifically directed against Hsp72.
Our results show that after treatment with the Hsp90 inhibitor 17-AAG for 24 h, myeloma cells increase the protein level of Hsp72. Combination treatment with KNK437 or triptolide blocks this increase ( Figure 1a ) and results in a decrease in proliferation compared with treatment with 17-AAG alone. Using a series of 16 concentrations of these agents applied in combination for a period of 4 days, we demonstrate that the concomitant application of 17-AAG with either of these compounds induces either additive or synergistic, antiproliferative effects (Figure 1b) . These effects are not seen in normal, human mononuclear cells (data not shown). We go on to show that both KNK437 and triptolide act synergistically with 17-AAG to increase the induction of apoptosis, as assessed by trypan blue exclusion and annexin V/PI staining (Figure 1c) . Cell cycle analysis demonstrated that single-agent treatment with 17-AAG induced a G2 cell cycle arrest. However, the combination of triptolide with 17-AAG overcomes this arrest creating an increase in the sub-G1 cell population, indicative of increased cell death (data not shown).
To determine the mechanism underlying the increase in apoptosis and decrease in cell proliferation induced by these inhibitors, we examined the cellular stress/UPR pathway and the caspase-dependent apoptotic pathways. Previously we have shown that Hsp90 inhibition in myeloma cells results in the induction of endoplasmic reticulum stress and UPR activation, leading to cell death via activation of the ER resident transmembrane protein kinase (PERK) branch of the UPR and the delivery of a proapoptotic signal via CCAAT/enhancer binding protein homologues protein (CHOP). In this study, we show that treatment with 17-AAG or triptolide alone induced upregulation of CHOP mRNA levels over a 24-h period (Figure 1d ). Concomitant treatment with both agents resulted in a sustained increase in CHOP mRNA expression, above those seen with either agent alone, suggesting that this is one mechanism by which the combination enhances apoptosis.
Activation of the Inositol requiring enzyme 1 (IRE1) branch of the UPR results in the splicing of X-box binding protein 1 (XBP1) to its active form, spliced XBP1 (XBP1s), which delivers a prosurvival signal. 4 We show that 17-AAG induced rapid, transient cleavage of XBP1,whereas triptolide induced XBP1 cleavage that was sustained for up to 24 h (Figure 1d) . Cleavage of XBP1 induced by the drug combination was readily detected, sustained and stronger than that induced by single agent therapy. However, by 24 h XBP1s was undetectable and a decrease in the total level of XBP1 was noted. These results suggest that by 24 h, the combination of agents has tipped the survival/apoptosis balance of UPR signaling towards cell death with an increase in the levels of pro-apoptotic CHOP and a decrease in the level of prosurvival XBP1s.
17-AAG activates both the intrinsic (caspases 9 and 3) and extrinsic caspase (caspases 8 and 3) pathways within 4 h of treatment (Figure 1e ). Triptolide alone induces cleavage of caspases 9, 8 and 3 but only after 24 h of treatment. As expected, the combination of agents induced cleavage of both sets of caspases at 4 h which is sustained. Importantly, the combination of 17-AAG and triptolide induced a more significant cleavage of caspases 9 and 3 than of caspase 8, suggesting that the combination potentiates cell death via sustained and enhanced activation of predominantly the intrinsic caspase-dependent cell death pathway. The validity of this observation was confirmed using the caspase inhibitor Z-VAD-FMK, which showed that only a minority of cell death occurs via a caspase-dependent mechanism in response to 17-AAG treatment alone, whereas the majority of cell death in response to triptolide alone or the combination occurs via a caspase-dependent mechanism (Figure 1e ).
As triptolide is primarily an inhibitor of Heats Shock Factor 1 (HSF1)-mediated heat shock response and not a specific inhibitor of Hsp72, we determined the specific effects of Hsp72 knockdown using shRNA. Using a transient expression system a number of shRNAs were found to successfully knockdown expression of Hsp72 in H929 cells (Figure 1f) . To verify whether knockdown of Hsp72 increased the efficacy of Hsp90 inhibitors in myeloma, we tested the effect of 17-AAG on the proliferation of cells transfected with Hsp72 shRNAs compared with those transfected with a scrambled shRNA. We demonstrate that Hsp72 knockdown induced a considerable increase, of up to 40%, in the susceptibility of myeloma cells to 17-AAG-induced apoptosis (Figure 1f) .
In this work, we demonstrate that the combination of Hsp90 inhibitors with inhibitors of Hsp72 induction, act synergistically to kill myeloma cells. This observation is compatible with the current understanding of the function of Hsp72, which interacts with members of the intrinsic apoptotic pathway, such as Bax, to prevent release of pro-apoptotic molecules from the mitochondria and with Apaf-1, blocking the recruitment of procaspase 9 to the apoptosome. In addition, it also associates with and inhibits precursor forms of caspases 3 and 7.
5 Thus inhibition of Hsp72 results in an increase in caspase-dependent cell death. In addition, we show that combining inhibitors of Hsp90 with inhibitors of Hsp72 induction enhances cell death through modulation of the endoplasmic reticulum stress pathway and the UPR. We demonstrate increased expression of CHOP mRNA, suggesting that the combination efficiently induces cell death via the PERK branch of the UPR, which is initiated through the effects of Bax on mitochondria and the subsequent initiation of the mitochondrial-dependent cell death signaling cascades. When this pathway is activated by 17-AAG alone, it is normally interrupted downstream of CHOP by the Hsp70-DnaJ chaperone complex which inhibits Bax translocation. However, this inhibitory effect is overcome by the combined use of Hsp inhibitors and contributes to their synergistic effects. Further evidence of cell death signaling via the UPR comes from the demonstration that the drug combination induces earlier and stronger XBP1 cleavage than either drug alone. However, this early pro-survival effect is not maintained and subsequent downregulation of XBP1 promotes increased cell death.
We confirm that the effects on cell death seen with the chemical inhibitors of Hsp72 induction are a direct effect of Hsp72 silencing using shRNA. shRNA gene silencing of Hsp72 increased the susceptibility of myeloma cells to 17-AAGinduced cell death in a manner similar to that seen with the chemical inhibitors. This result is in line with work in other cell types including colon and ovarian carcinoma cells, confirming the potential of Hsp72 as a molecular target. 6 A number of high throughput screens have identified more specific Hsp72 small molecule inhibitors which are suitable for clinical use. [7] [8] [9] Using these drugs either in combination with Hsp90 inhibitors or other drugs which induce cellular stress and upregulate Hsp72, offers a way to increase clinical efficacy. Our work specifically demonstrates that combinations of specific small molecule inhibitors of Hsp's 90 and 72 may be particularly effective against immunoglobulin producing, myeloma cells, as these cells intrinsically rely heavily upon heat shock proteins to deal with their protein load and redirect and degrade misfolded proteins.
Imatinib mesylate (STI-571, Gleevec, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is now used worldwide for the treatment of chronic myelogenous leukemia (CML) with great success; however, CML often progresses or relapses because of the development of imatinib resistance after long-term treatment. The main cause for imatinib resistance is the acquisition of point mutations in the genetic sequences encoding the Abl kinase domain.
1 Therefore, the discovery and development of a new generation of Bcr-Abl inhibitors capable of overriding imatinib resistance is of utmost importance.
On the basis of the crystallographic structure of the imatinib-Abl complex, we identified a novel inhibitor of Bcr-Abl called HH-GV-678 (Figure 1a) . The kinase activities of c-Abl, PDGFRb (platelet derived growth factor receptor-b) and c-Kit were inhibited by HH-GV-678 with IC 50 values of 1.2 ± 0.7, 307.6±259.0 and 665.5±306.8 nM; however, this drug had no effect on the kinase activities of vascular endothelial growth factor receptor 2/kinase insert domain receptor (VEGFR2/KDR), Flt3, Ret, VEGFR3, c-Src, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Imatinib had IC 50 values of 100.9 ± 91.8, 201.8 ± 23.6 and 361.8±40.0 nM for c-Abl, PDGFRb and c-Kit, respectively. Consistent with the in vitro results of a kinase assay, HH-GV-678 completely blocked cellular Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation in K562 leukemia cells, with much more potent activity than did imatinib (30 vs 300 nM) (Figure 1b) . However, HH-GV-678 inhibited the phosphorylations of c-Kit and PDGFRb with less potency (Supplementary Figure 1) and had no effect on the phosphorylation of EGFR, VEGFR, c-Src or HER2 (Supplementary Figure 2) . These data indicate that HH-GV-678 is a selective inhibitor of the c-Abl kinase and has much stronger activity than imatinib. were incubated with HH-GV-678 or imatinib for 3 h. Total cell lysates were analyzed by western blotting, and the levels of phospho-and un-phosphoproteins were determined using specific antibodies.
